MR‑guided short‑course radiation with chemotherapy and surgery for unresectable locally advanced colon cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single‑arm phase I study will enroll about 20 patients with cT4N0‑2M0 colon adenocarcinoma to receive MR‑Linac adaptive short‑course radiotherapy (25 Gy in 5 fractions), followed by neoadjuvant chemotherapy (mFOLFOX6 or XELOX), radical surgery, and postoperative chemotherapy. The study will track surgical R0 resection rate, pathologic or clinical complete response rates, progression‑free and overall survival, and treatment‑related adverse events. An initial run‑in feasibility phase will monitor protocol adherence, adaptive‑plan success, and accrual before proceeding to the definitive phase. The design focuses on safety, technical feasibility of the MR‑Linac workflow, and early signals of efficacy in converting unresectable tumors to resectable status.

Why it matters

Who can join: the full rules

Inclusion criteria:

1. Patients over 18 years old
2. Patients can remain in a stationary position on the treatment bed for 1-1.5 hours
3. ECOG score 0-1
4. Pathological diagnosis of colon adenocarcinoma, clinical stage cT4N0-2M0
5. Organ function is normal, and the following conditions are required: white blood cell count ≥3.5×10\^9/L; platelet count ≥100×10\^9/L; hemoglobin ≥90g/L. Total bilirubin level ≤1.5× upper limit of normal (ULN); AST and ALT levels ≤2.5 × ULN; endogenous creatinine clearance rate: 56-122ml/min; serum creatinine \<1.0× ULN; serum albumin ≥30g/L.
6. Able to adhere to the study protocol during the research period
7. Signed written informed consent

Exclusion Criteria:

1. Patients with dMMR or MSI-H
2. Presence of other types of tumors in addition to colon adenocarcinoma
3. Claustrophobia or inability to undergo MRI or treatment due to the presence of metal implants or other reasons
4. Distant metastasis (M1)
5. Pregnant or lactating women
6. Previous anti-tumor treatment
7. Concurrent use of prohibited drugs for treatment
8. Known history of positive human immunodeficiency virus testing or known acquired immunodeficiency syndrome.
9. Clinically significant (i.e., active) cardiovascular disease: cerebrovascular accident/stroke (\<6 months prior to enrollment), myocardial infarction (\<6 months prior to enrollment), unstable angina pectoris, congestive heart failure (≥New York Heart Association class II) or severe arrhythmia requiring medication treatment
10. Individuals with uncontrolled epilepsy, central nervous system disorders or a history of mental illness, whose clinical severity may hinder signing informed consent or affect patient compliance with oral medication according to the investigator's judgement
11. Organ transplant surgery requiring immunosuppressive therapy
12. Severe, uncontrolled recurrent infections or other severe, uncontrolled comorbidities

Where it's running

• Sichuan Cancer Hospital & Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China.
  Chengdu, Sichuan, China Recruiting

Study contacts

• Study coordinator: Qian - Peng, chief physician
• Email: pengqian@scszlyy.org.cr
• Phone: +086 17708130617

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• RIG-101 for healthy adults and people with asthma

  This trial will test whether RIG-101 is safe, well tolerated, and can protect healthy adults and adults with asthma from a controlled viral exposure.

  Recruiting at 2 sites Phase 1/2 RIGImmune Inc. · London and 1 other locations · NCT07488897

• Evaluating a scar gel for preventing hypertrophic scars

  This study tests a new scar gel to see if it can help prevent raised scars in people with recent scars compared to a standard product.

  Recruiting Phase 1/2 Herbarium Laboratorio Botanico Ltda · Osasco, São Paulo and 1 other locations · NCT06751433

• Using stereotactic radiotherapy for treating thoracic tumors

  This study tests if a special type of radiation therapy can safely treat chest tumors that are 5cm or smaller while protecting nearby healthy tissue.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT05349552

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.